Search Clinical Trials in the EU

Duration

Visits

Confirmation phase (III)

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

181-200 of 1,307 trials

Atrial Fibrillation: Abelacimab Treatment Study

We are studying whether abelacimab can help high-risk patients with atrial fibrillation who cannot take oral blood thinners. The goal is to see if it reduces the risk of strokes and other serious complications compared to a placebo.

Atrial Fibrillation>2 yearsConfirmation phase (III)>20 visits Investigational Medicines Cost Reimbursement Partially RemoteCardiologyInternal Medicine

Pleural Mesothelioma: Volrustomig with Carboplatin and Pemetrexed

We are studying a new treatment combination for patients with unresectable pleural mesothelioma. The goal is to see if it works better than current standard care options.

Unresectable Pleural Mesothelioma>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteOncology

Ureter Visualization: Nizaracianine Triflutate in Surgery

We are studying a new intravenous drug to help surgeons see the ureters more clearly during abdominopelvic surgeries. This may improve safety and reduce the need for invasive procedures.

Urinary Tract ImagingEfficacy phase (II)Confirmation phase (III)No Placebo Standard MedicinesOtolaryngologyUrology

Tenosynovial Giant Cell Tumor: Study of ABSK021

We are investigating a new treatment, ABSK021, for patients with Tenosynovial Giant Cell Tumor to see if it is safe and effective compared to a placebo. The study will also assess how it affects tumor size and patient mobility.

Tenosynovial Giant Cell Tumor6-12 monthsConfirmation phase (III)6-10 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteOncology

Endometrial Cancer: RAINBO Treatment Study

We are exploring a new treatment approach for patients with endometrial cancer based on their molecular features. The goal is to see if this can improve survival rates and reduce the chance of cancer returning.

Mismatch Repair Deficient High-Risk Endometrial Cancer>2 yearsConfirmation phase (III)11-15 visits No Placebo Standard MedicinesGynecology and ObstetricsOncology

Melanoma Treatment: ABP 206 vs. OPDIVO

We are evaluating a new treatment, ABP 206, for patients with advanced melanoma who have not been treated before. The study aims to see how well it works and how safe it is compared to OPDIVO.

Metastatic Melanoma>2 yearsConfirmation phase (III)>20 visits No Placebo Investigational Medicines Partially RemoteOncology

Osteogenesis Imperfecta: Romosozumab vs. Bisphosphonates

We are studying whether romosozumab can reduce fractures and improve bone density in children and adolescents with osteogenesis imperfecta compared to bisphosphonates. This trial will help us understand the safety and effectiveness of this new treatment.

Brittle Bone Disease1-2 yearsConfirmation phase (III)16-20 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteOrthopedics and TraumatologyPediatrics

Biliary Tract Cancer: GAP Chemotherapy Study

We are studying whether a combination of chemotherapy before surgery helps patients with biliary tract cancers live longer and have better outcomes than those who undergo surgery right away.

Biliary Tract CancerEfficacy phase (II)Confirmation phase (III)No Placebo Standard MedicinesOncology

Metastatic Non-Small Cell Lung Cancer: Volrustomig Plus Chemotherapy

We are studying whether the new drug volrustomig combined with chemotherapy is more effective than pembrolizumab plus chemotherapy for patients with metastatic non-small cell lung cancer. This trial focuses on those with low PD-L1 levels.

Metastatic Non-Small Cell Lung Cancer≤3 monthsConfirmation phase (III)No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncology

Hearing Loss Prevention: Sodium Thiosulfate for Chemotherapy Patients

We are studying whether transtympanic sodium thiosulfate can help prevent hearing loss in patients receiving cisplatin chemotherapy. This trial will compare its effects on hearing with those of untreated ears.

Head and Neck Cancer3-6 monthsConfirmation phase (III)No Placebo Standard MedicinesOncologyOtolaryngology

Tislelizumab for Cancer Patients with Residual Disease

We are studying whether tislelizumab can help cancer patients who still have detectable disease after standard treatment. The goal is to see if it improves their chances of staying cancer-free compared to a placebo.

Pancreatic CancerSoft Tissue SarcomaNon-Small Cell Lung Cancer>2 yearsConfirmation phase (III)16-20 visits Standard Medicines Partially RemoteGastroenterologyOncologyPulmonology

Metastatic Renal Cell Carcinoma: Treatment Comparison Study

We are comparing two treatment combinations for patients with metastatic renal cell carcinoma to see which one improves survival and quality of life. This study is for those who have not received treatment before and have specific risk factors.

Metastatic Renal Cell CarcinomaConfirmation phase (III)11-15 visits No Placebo Standard MedicinesInternal MedicineOncology

Oligometastatic Non-Small Cell Lung Cancer: Immunotherapy with Local Treatments

We are studying whether adding a local treatment to standard immunotherapy helps improve survival for patients with oligometastatic non-small cell lung cancer. This trial will also look at quality of life and side effects.

Synchronous Oligometastatic Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)11-15 visits No Placebo Standard MedicinesOncologyPulmonology

Sjögren’s Syndrome: Deucravacitinib Study

We are testing a new medication, deucravacitinib, for adults with active Sjögren’s Syndrome to see if it improves symptoms better than a placebo. The study also looks at the safety and tolerability of this treatment.

Sjogren's Syndrome1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access Standard Medicines Cost ReimbursementRheumatology

Menière's Disease: Methylprednisolone Injection Study

We are investigating whether an injection of methylprednisolone can reduce vertigo attacks in patients with Menière's disease. This study will also assess its effects on hearing and overall quality of life.

Menière's Disease1-2 yearsConfirmation phase (III)≤5 visits Standard Medicines Partially RemoteOtolaryngology

Lung Cancer Treatment: MK-2870 with Pembrolizumab

We are comparing a new combination treatment for metastatic non-small cell lung cancer to standard therapy. This study aims to see if the combination improves survival and quality of life for patients with high PD-L1 levels.

Metastatic Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)≤5 visits Post-Trial Drug Access Investigational MedicinesOncology

Follicular Lymphoma: Tisagenlecleucel vs. Standard Care

We are studying a new treatment called tisagenlecleucel for adults with relapsed or refractory follicular lymphoma. The goal is to see if it helps patients live longer and respond better than current standard treatments.

Follicular Lymphoma>2 yearsConfirmation phase (III)6-10 visits No Placebo Standard Medicines Partially RemoteHematologyOncology

Chronic Lung Allograft Dysfunction: Belumosudil Tablets

We are testing belumosudil tablets to see if they improve lung function in adults with chronic lung allograft dysfunction after lung transplantation. The study will also look at how this treatment affects exercise capacity and overall health.

Lung Transplant Rejection6-12 monthsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicinePulmonology

Cholestatic Pruritus: Linerixibat Treatment Study

We are studying the long-term safety and tolerability of linerixibat for people with cholestatic pruritus due to primary biliary cholangitis. The trial also looks at how this treatment affects quality of life and itch relief.

Cholestatic PruritusPrimary Biliary Cholangitis1-2 yearsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementGastroenterologyHepatology

Panguian Clinical Trial

We are exploring a new treatment in this clinical trial. Participants will help us understand its effects and potential benefits.

Rheumatoid Arthritis>2 yearsConfirmation phase (III)Monitoring phase (IV)Orthopedics and Traumatology

Search Clinical Trials in the European Union